Trial Profile
Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 10 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 26 Feb 2013 Planned End Date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
- 01 Nov 2011 Planned end date changed from 1 May 2012 to 1 May 2013.